Seregin S - Search Results

1

Adenovirus vectors for renal-targeted gene delivery.

Appledorn DM, Seregin S, Amalfitano A. Appledorn DM, et al. Among authors: seregin s. Contrib Nephrol. 2008;159:47-62. doi: 10.1159/000125581. Contrib Nephrol. 2008. PMID: 18391584 Review.

2

CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies.

Seregin SS, Aldhamen YA, Appledorn DM, Schuldt NJ, McBride AJ, Bujold M, Godbehere SS, Amalfitano A. Seregin SS, et al. Gene Ther. 2009 Oct;16(10):1245-59. doi: 10.1038/gt.2009.77. Epub 2009 Jun 25. Gene Ther. 2009. PMID: 19554032 Free PMC article.

3

Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Seregin SS, Appledorn DM, McBride AJ, Schuldt NJ, Aldhamen YA, Voss T, Wei J, Bujold M, Nance W, Godbehere S, Amalfitano A. Seregin SS, et al. Mol Ther. 2009 Apr;17(4):685-96. doi: 10.1038/mt.2008.297. Epub 2009 Jan 27. Mol Ther. 2009. PMID: 19174760 Free PMC article.

4

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.

Seregin SS, Amalfitano A. Seregin SS, et al. Expert Opin Biol Ther. 2009 Dec;9(12):1521-31. doi: 10.1517/14712590903307388. Expert Opin Biol Ther. 2009. PMID: 19780714 Review.

5

beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2.

Seregin SS, Appledorn DM, Patial S, Bujold M, Nance W, Godbehere S, Parameswaran N, Amalfitano A. Seregin SS, et al. Virus Res. 2010 Jan;147(1):123-34. doi: 10.1016/j.virusres.2009.10.023. Epub 2009 Nov 6. Virus Res. 2010. PMID: 19896992 Free PMC article.

6

A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target.

Appledorn DM, Aldhamen YA, Depas W, Seregin SS, Liu CJ, Schuldt N, Quach D, Quiroga D, Godbehere S, Zlatkin I, Kim S, McCormick JJ, Amalfitano A. Appledorn DM, et al. Among authors: seregin ss. PLoS One. 2010 Mar 8;5(3):e9579. doi: 10.1371/journal.pone.0009579. PLoS One. 2010. PMID: 20221448 Free PMC article.

7

Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor.

Seregin SS, Hartman ZC, Appledorn DM, Godbehere S, Jiang H, Frank MM, Amalfitano A. Seregin SS, et al. J Innate Immun. 2010;2(4):353-9. doi: 10.1159/000284368. Epub 2010 Feb 11. J Innate Immun. 2010. PMID: 20375551 Free PMC article.

8

Use of DAF-displaying adenovirus vectors reduces induction of transgene- and vector-specific adaptive immune responses in mice.

Seregin SS, Aldhamen YA, Appledorn DM, Zehnder J, Voss T, Godbehere S, Amalfitano A. Seregin SS, et al. Hum Gene Ther. 2011 Sep;22(9):1083-94. doi: 10.1089/hum.2010.218. Epub 2011 Apr 18. Hum Gene Ther. 2011. PMID: 21388344 Free PMC article.

9

Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.

Seregin SS, Amalfitano A. Seregin SS, et al. Curr Pharm Des. 2011;17(24):2558-74. doi: 10.2174/138161211797247578. Curr Pharm Des. 2011. PMID: 21774776 Review.

10

Improving adenovirus based gene transfer: strategies to accomplish immune evasion.

Seregin SS, Amalfitano A. Seregin SS, et al. Viruses. 2010 Sep;2(9):2013-2036. doi: 10.3390/v2092013. Epub 2010 Sep 24. Viruses. 2010. PMID: 21994718 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page